Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

Phase 1

Completed

• Conditions: Pseudomonas Infection
• Interventions: Drug: Ciprofloxacin (Cipro, BAYQ3939)

• Registration Number: NCT00910351
• Lead Sponsor: Bayer

Brief Summary

Ciprofloxacin PulmoSphere Inhalation Powder appears to be an effective and adequate antibiotic treatment for cystic fibrosis patients with P. aeruginosa colonisation. This planned study is the first study on the use of this new Ciprofloxacin PulmoSphere Inhalation Powder in the pediatric population of 6 to 12 years of age.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study First Submitted: 2009-05-28
• Study First Submitted QC: 2009-05-28
• Study First Posted: 2009-05-29
• Study Start: 2009-07
• Primary Completion: 2010-10
• Study Completion: 2010-10
• Status Verified: 2013-11
• Last Update Submitted: 2013-11-20
• Last Update Posted: 2013-11-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

• Male or female patients with cystic fibrosis confirmed by genetic testing and / or by sweat test
• Colonization with P. aeruginosa confirmed in sputum in the past 12 months
• Cohort 1: greater than or equal to 18 years of age.
• Cohort 2: 6 - 12 years of age (inclusive)
• Normal Body Mass Index: BMI between 14.5 and 30 kg/m2, but in no case lower than the 30th percentile for age. Because CF patients are typically smaller than non-CF-patients, the normal body mass index will be based on standard CF foundation normal values for weight and sex.
• Patients who are able to understand and follow instructions and who are able to participate in the study for the entire period.
• Patients and legal representatives must have given their written informed consent to participate in the study after receiving adequate previous information and prior to any study specific procedures

Read More

Exclusion Criteria

• Patients with FEV1 < 35% of predicted. FEV1 (forced expiratory volume) is a measure of lung function. This exclusion will prohibit enrollment of patients with severely impaired lung function.
• Patients with Burkholderia cepacia colonization of their respiratory tract
• Patients with acute bronchopulmonary aspergillosis (ABPA)
• Patients on a lung transplant list
• Patients with acute pulmonary exacerbations
• Patients with severe liver cirrhosis
• Massive hemoptysis in the preceding 4 weeks
• A history of relevant diseases of vital organs, of the central nervous system, or other organs not related to the underlying disease
• Patients with a history of severe allergies, non-allergic drug reactions, or multiple drug allergies
• Patients with hypersensitivity to the investigational drug or to other quinolones and/ or to inactive constituents
• Patients with known intolerance to hypertonic saline or bronchodilators
• Concomitant inhalation therapy with antibiotics and / or concomitant systemic therapy with fluoroquinolones
• Women who are pregnant

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Arm 1	Ciprofloxacin (Cipro, BAYQ3939)	-

Primary Outcome Measures

Name	Time	Method
To investigate the safety and tolerability of inhaled ciprofloxacin given as single inhalation dose to pediatric CF patients, aged 6 - 12 years	Two weeks post screening

Secondary Outcome Measures

Name	Time	Method
To investigate the pharmacokinetics of ciprofloxacin in plasma and sputum after inhalation administration	Day 1